Heidelberg Pharma AG (ETR:HPHA)
Germany · Delayed Price · Currency is EUR 2.080
-0.070 (-3.26%)
Oct 26, 2026, 5:35 PM CET
Heidelberg Pharma AG Income Statement
Financials in millions EUR. Fiscal year is December - November.
Millions EUR. Fiscal year is Dec - Nov.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Nov '25 Nov 30, 2025 | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 |
Operating Revenue | 9.32 | 1.46 | 6.85 | 9.86 | 18.51 | 1.75 |
Other Revenue | 0 | - | - | - | - | 0.28 |
| 9.32 | 1.46 | 6.85 | 9.86 | 18.51 | 2.03 | |
Revenue Growth | 206.78% | -78.72% | -30.53% | -46.75% | 810.30% | -76.53% |
Cost of Revenue | 1.78 | 0.27 | 1.78 | 3.25 | 4.68 | 4.71 |
Gross Profit | 7.54 | 1.19 | 5.07 | 6.61 | 13.83 | -2.68 |
Selling, General & Admin | 6.88 | 7.61 | 6.74 | 6.22 | 5.99 | 4.48 |
Research & Development | 31.05 | 38.78 | 21.84 | 28.07 | 26.38 | 18.75 |
Other Operating Expenses | 2.45 | 3.73 | -1.68 | -0.14 | -0.24 | -0.07 |
Operating Expenses | 40.37 | 50.12 | 26.9 | 34.15 | 32.13 | 23.16 |
Operating Income | -32.83 | -48.93 | -21.83 | -27.55 | -18.29 | -25.84 |
Interest Expense | -0 | -0 | -0.14 | -0.76 | -0.84 | -0.49 |
Interest & Investment Income | 1.77 | 2.31 | 1.42 | 7.55 | 0.24 | - |
Earnings From Equity Investments | - | - | - | - | - | -0.01 |
Currency Exchange Gain (Loss) | 5.18 | 5.18 | -0.18 | -0.46 | 0.96 | 0 |
Other Non Operating Income (Expenses) | -2.68 | 0.08 | 0.12 | 0.21 | 0.06 | 0.09 |
EBT Excluding Unusual Items | -28.56 | -41.36 | -20.6 | -21.01 | -17.87 | -26.26 |
Gain (Loss) on Sale of Assets | 0 | 0 | 0 | 0.03 | 0.02 | - |
Other Unusual Items | 0.13 | 0.13 | 1.22 | 0.63 | 0.07 | 0.12 |
Pretax Income | -28.43 | -41.23 | -19.38 | -20.35 | -17.79 | -26.14 |
Income Tax Expense | 1.48 | 1.05 | - | - | 1.92 | - |
Net Income | -29.9 | -42.28 | -19.38 | -20.35 | -19.7 | -26.14 |
Net Income to Common | -29.9 | -42.28 | -19.38 | -20.35 | -19.7 | -26.14 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 46 | 47 | 47 | 47 | 37 | 33 |
Shares Outstanding (Diluted) | 46 | 47 | 47 | 47 | 37 | 33 |
Shares Change | -2.91% | 0.14% | 0.02% | 25.14% | 14.56% | 8.72% |
EPS (Basic) | -0.65 | -0.91 | -0.42 | -0.44 | -0.53 | -0.80 |
EPS (Diluted) | -0.66 | -0.91 | -0.42 | -0.44 | -0.53 | -0.80 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Nov '25 Nov 30, 2025 | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 |
Free Cash Flow | -19.11 | -31.73 | -30.04 | -34.61 | -9.45 | -27.85 |
Free Cash Flow Per Share | -0.42 | -0.68 | -0.65 | -0.74 | -0.25 | -0.86 |
Gross Margin | 80.93% | 81.31% | 74.00% | 67.01% | 74.72% | -131.69% |
Operating Margin | -352.32% | -3357.60% | -318.71% | -279.41% | -98.81% | -1270.65% |
Profit Margin | -320.91% | -2901.15% | -282.98% | -206.38% | -106.42% | -1285.20% |
Free Cash Flow Margin | -205.12% | -2177.08% | -438.64% | -351.07% | -51.03% | -1369.57% |
EBITDA | -32.57 | -48.23 | -21.1 | -26.84 | -17.7 | -25.2 |
EBITDA Margin | - | - | - | -272.20% | -95.63% | - |
D&A For EBITDA | 0.26 | 0.71 | 0.73 | 0.71 | 0.59 | 0.64 |
EBIT | -32.83 | -48.93 | -21.83 | -27.55 | -18.29 | -25.84 |
EBIT Margin | - | - | - | -279.41% | -98.81% | - |
Revenue as Reported | 12.03 | 6.93 | 11.96 | 16.8 | 19.86 | 2.31 |